Randomized phase II trial of intravenous R05137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168) Meeting Abstract
| Authors: | Yen, C. J.; Daniele, B.; Kudo, M.; Merle, P.; Park, J. W.; Ross, P. J.; Peron, J. M.; Ebert, O.; Chan, S. L.; Tung, R.; Poon, P.; Colombo, M.; Okusaka, T.; Ryoo, B. Y.; Minguez, B.; Tanaka, T.; Ohtomo, T.; Rutman, O.; Chen, Y. C.; Lee, R. M.; Abou-Alfa, G. K. |
| Abstract Title: | Randomized phase II trial of intravenous R05137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203265 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.4102 |
| Notes: | Meeting Abstract: 4102 -- Source: Wos |
